Karus Therapeutics giving lecture at 10th Annual Symposium – Next Generation Histone Deacetylase Inhibitors

Oxford, UK, 7 September 2016 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced its CSO will be attending and delivering a lecture at the 9th Annual Kinase Inhibitor Discovery conference, Boston, USA, 19 September 2016.

Stephen Shuttleworth, Karus’s CSO, will be lecturing in the session Role of HDACI in Modulating Cancer Pathways, “Design and Development of Novel, Orally-Active, Selective HDAC6 Inhibitors for the Treatment of Cancer” at 10:40am on Monday 19 September 2016.

For more information on Karus’s presentations or for media enquiries, please contact karus@instinctif.com.